Archives of disease in childhood. Fetal and neonatal edition · 2026
Effect of brewers' yeast or beta-glucan derived from Saccharomyces cerevisiae on breast milk supply following preterm birth: the BLOOM randomised controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Grzeskowiak Luke, Williams Lauren, Rumbold Alice, Simpson Bronni, Kam Renee L, Yelland Lisa Nicole, Dansie Kathryn, Ingman Wendy V, Keir Amy, Martinello Kathryn A, Amir Lisa H
Аннотация
OBJECTIVE: Breast milk is the optimal source of nutrition for preterm infants; however, low breast milk production is common following a preterm birth. This study aimed to determine if taking brewers' yeast or beta-glucan improves daily expressed breast milk volume.
DESIGN: Randomised, blinded, parallel, placebo-controlled trial.
SETTING: Three Australian tertiary-level neonatal units.
PATIENTS: Mothers with a singleton or twin pregnancy who gave birth at <34 weeks' gestation.
INTERVENTIONS: Mothers were randomised within 72 hours of birth into three parallel groups in a 1:1:1 ratio to receive either brewers' yeast, beta-glucan or placebo capsules for 7 days.
MAIN OUTCOME MEASURE: Total expressed breast milk volume over a 24-hour period on day 7 of intervention.
RESULTS: A total of 105 mothers underwent randomisation between August 2022 and April 2024 (36 brewers' yeast, 35 beta-glucan and 34 placebo). The adjusted mean difference in daily expressed breast milk volume was 94 mL/day (95% CI -51 mL/day to 239 mL/day) between the brewers' yeast and placebo groups and -25 mL/day (95% CI -173 mL/day to 123 mL/day) between the beta-glucan and placebo groups. Maternal side effects were similar across groups.
CONCLUSION: We found no clear effect of short-term administration of brewers' yeast or beta-glucan on breast-milk production following preterm birth; both interventions were well tolerated. Given the small sample size, these findings do not rule out the possibility of a clinically meaningful benefit of brewers' yeast and suggest further research with a larger sample size may be warranted to clarify the potential clinical impact.
TRIAL REGISTRATION NUMBER: ACTRN12622000968774.
DESIGN: Randomised, blinded, parallel, placebo-controlled trial.
SETTING: Three Australian tertiary-level neonatal units.
PATIENTS: Mothers with a singleton or twin pregnancy who gave birth at <34 weeks' gestation.
INTERVENTIONS: Mothers were randomised within 72 hours of birth into three parallel groups in a 1:1:1 ratio to receive either brewers' yeast, beta-glucan or placebo capsules for 7 days.
MAIN OUTCOME MEASURE: Total expressed breast milk volume over a 24-hour period on day 7 of intervention.
RESULTS: A total of 105 mothers underwent randomisation between August 2022 and April 2024 (36 brewers' yeast, 35 beta-glucan and 34 placebo). The adjusted mean difference in daily expressed breast milk volume was 94 mL/day (95% CI -51 mL/day to 239 mL/day) between the brewers' yeast and placebo groups and -25 mL/day (95% CI -173 mL/day to 123 mL/day) between the beta-glucan and placebo groups. Maternal side effects were similar across groups.
CONCLUSION: We found no clear effect of short-term administration of brewers' yeast or beta-glucan on breast-milk production following preterm birth; both interventions were well tolerated. Given the small sample size, these findings do not rule out the possibility of a clinically meaningful benefit of brewers' yeast and suggest further research with a larger sample size may be warranted to clarify the potential clinical impact.
TRIAL REGISTRATION NUMBER: ACTRN12622000968774.